Cwestiwn ysgrifenedig WQ96271
- Gofynnwyd gan
- James EvansCeidwadwyr
- I'w ateb gan
- Cabinet Secretary for Health and Social Care
- Cyflwynwyd
- Dyddiad ateb
- Atebwyd
- Amser i'w ateb
- 8 diwrnod
Cwestiwn
Mae'r cwestiwn a'r ateb yn Saesneg gan nad oes fersiwn Gymraeg ar gael.
Will the Cabinet Secretary confirm whether the gene-editing therapy Casgevy (exagamglogene autotemcel) is now available to eligible patients with sickle cell disease and transfusion-dependent beta thalassaemia in Wales?
Ateb
Atebwyd gan Cabinet Secretary for Health and Social Care
In line with recommendations by the National Institute for Health and Care Excellence, Exagamglogene Autotemcel is available for eligible Welsh patients for both transfusion dependent beta-thalassaemia and sickle cell disease, through referral by haematology teams to designated specialised centres.